264 related articles for article (PubMed ID: 19720898)
1. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
Montagnani F; Migali C; Fiorentini G
J Clin Oncol; 2009 Oct; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
[No Abstract] [Full Text] [Related]
2. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
4. Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.
Tyagi P
Clin Colorectal Cancer; 2006 Sep; 6(3):189-91. PubMed ID: 17026787
[No Abstract] [Full Text] [Related]
5. Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint.
Robert NJ
Breast Cancer Res Treat; 2010 Jul; 122(1):9-10. PubMed ID: 20495865
[No Abstract] [Full Text] [Related]
6. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
Giantonio BJ
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Hochster HS
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
Whyte S; Pandor A; Stevenson M; Rees A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
[TBL] [Abstract][Full Text] [Related]
10. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
Matsusaka S; Suenaga M; Mishima Y; Takagi K; Terui Y; Mizunuma N; Hatake K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):763-8. PubMed ID: 21170650
[TBL] [Abstract][Full Text] [Related]
11. Managing patients with metastatic colorectal cancer on bevacizumab.
Lemmens L; Claes V; Uzzell M
Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of chemotherapy combined with bevacizumab for metastatic colorectal cancer].
Momoi A; Motomura S; Hashimoto C; Takasaki H; Takemura S; Takagi S; Akaike M
Gan To Kagaku Ryoho; 2011 Jan; 38(1):79-83. PubMed ID: 21368462
[TBL] [Abstract][Full Text] [Related]
13. Current role of bevacizumab in colorectal cancer.
Saltz L
Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
[No Abstract] [Full Text] [Related]
14. Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.
Coriat R; Mir O; Chaussade S; Goldwasser F
Dig Liver Dis; 2011 Mar; 43(3):248-9. PubMed ID: 21145299
[No Abstract] [Full Text] [Related]
15. Bevacizumab in colorectal cancer.
Sonpavde G
N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15483292
[No Abstract] [Full Text] [Related]
16. Bevacizumab in the treatment of metastatic colorectal cancer.
Caprioni F; Fornarini G
Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
[TBL] [Abstract][Full Text] [Related]
17. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
18. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Beatty GL; Giantonio BJ
Expert Rev Anticancer Ther; 2008 May; 8(5):683-8. PubMed ID: 18471041
[TBL] [Abstract][Full Text] [Related]
19. [Complications of chemotherapy in combination with bevacizumab for treating metastatic colorectal cancer].
Manikhas GM; Korolenko VO; Al'-Nekhmi AA; Antimonik NIu
Vopr Onkol; 2010; 56(5):613-6. PubMed ID: 21137245
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis inhibitors in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]